RT Conference Proceedings
T1 Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes
A1 Hui, R.
A1 Ozguroglu, M.
A1 Villegas, A.
A1 Daniel, D.
A1 Vicente, D.
A1 Murakami, S.
A1 Ryden, A.
A1 Zhang, Y.
A1 Dennis, P.
A1 Antonia, S.
PB Elsevier science inc
SN 1556-0864
YR 2018
FD 2018-04-01
LK https://hdl.handle.net/10668/27571
UL https://hdl.handle.net/10668/27571
LA en
DS RISalud
RD Apr 5, 2025